DEFERASIROX AND DEFEROXAMINE COMBINATION THERAPY: A CASE OF MANAGEMENT OF IRON OVERLOAD IN MYELODYSPLASTIC SYNDROME IN AN HEPATOPATHIC PATIENT.

被引：0
|
作者：
Cerchione, C. [1 ]
Cerciello, G. [1 ]
Della Pepa, R. [1 ]
Matarazzo, M. [1 ]
Alfinito, F. [1 ]
Pane, F. [1 ]
机构：
[1] Univ Federico II, Naples, Italy
来源：
HAEMATOLOGICA | 2012年 / 97卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1847
引用
收藏
页码：713 / 713
页数：1
相关论文
共 50 条
  • [21] IRON CHELATION THERAPY WITH THE DEFERIPRONE PLUS DEFEROXAMINE REGIMEN USED IN PATIENTS WITH THALASSEMIA SAFELY AND EFFECTIVELY REVERSED IRON OVERLOAD-RELATED HEART FAILURE IN A PATIENT WITH MYELODYSPLASTIC SYNDROME
    Pinto, V.
    Balocco, M.
    Quintino, S.
    Lamagna, M.
    Carrara, P.
    Forni, G. L.
    HAEMATOLOGICA, 2015, 100 : 105 - 106
  • [22] Guidelines on iron chelation therapy in patients with myelodysplastic syndrome and transfusion iron overload
    Gattermann, N.
    LEUKEMIA RESEARCH, 2007, 31 : S15 - S16
  • [23] Study of treatment with deferoxamine (DFX) in subcutaneous perfusion for patients diagnosed of myelodysplastic syndrome with iron overload.
    Villegas, A
    Ropero, P
    Barrio, CG
    Gonzalez, FA
    Arrizabalaga, B
    Remacha, A
    del Arco, A
    Gilsanz, F
    Peñalver, MA
    Murga, MJ
    BLOOD, 2003, 102 (11) : 333B - 333B
  • [24] CONIFER - Non-Interventional Study to Evaluate Therapy Monitoring During Deferasirox Treatment of Iron Toxicity in Myelodysplastic Syndrome Patients with Transfusional Iron Overload
    Bruch, Harald-Robert
    Dencausse, Yves
    Hessling, Joerg
    Michl, Gerlinde
    Schlag, Rudolf
    Skorupa, Alexandra
    Schneider-Schranz, Cornelia
    Wolf, Sebastian
    Schulte, Clemens
    Tesch, Hans
    ONCOLOGY RESEARCH AND TREATMENT, 2016, 39 (7-8) : 424 - 431
  • [25] A case of transfusion independence in a patient with myelodysplastic syndrome using deferasirox, sustained for two years after stopping therapy
    Sanford, D.
    Hsia, C. C.
    Current Oncology, 2015, 22 (02) : E128 - E132
  • [26] Efficacy and safety of deferoxamine, deferasirox and deferiprone triple iron chelator combination therapy for transfusion-dependent β-thalassaemia with very high iron overload: a protocol for randomised controlled clinical trial
    Premawardhena, Anuja
    Perera, Chamodi
    Wijethilaka, Muditha Nayana
    Wanasinghe, Sakuni Keshani
    Rajakaruna, R. H. M. G.
    Samarasinghe, R. A. N. K. K.
    Williams, Senani
    Mettananda, Sachith
    BMJ OPEN, 2024, 14 (02):
  • [27] Iron chelation therapy with deferasirox (Exjade®, ICL670) or deferoxamine is effective in reducing iron overload in patients with advanced fibrosis and cirrhosis.
    Angelucci, E
    Turlin, B
    Canatan, D
    Mangiagli, A
    De Sanctis, V
    Meddeb, B
    Rose, C
    Soulieres, D
    Cunningham, M
    Gattermann, N
    Ressayre-Djaffer, C
    Rabault, B
    Ford, J
    BLOOD, 2005, 106 (11) : 757A - 758A
  • [28] Clinical consequences of iron overload in patients with myelodysplastic syndromes: the case for iron chelation therapy
    Shammo, Jamile M.
    Komrokji, Rami S.
    EXPERT REVIEW OF HEMATOLOGY, 2018, 11 (07) : 577 - 586
  • [29] Improving clinical outcome in patients with myelodysplastic syndrome and iron overload using iron chelation therapy
    Leitch, Heather A.
    LEUKEMIA RESEARCH, 2007, 31 : S7 - S9
  • [30] Effect of iron chelator deferasirox on chronic anemia and thrombocytopenia in a transfusion-dependent patient with myelodysplastic syndrome
    Nishiuchi, Takamasa
    Okutani, Yuichi
    Fujita, Toshikazu
    Yoshida, Kazuya
    Ohnishi, Hiroaki
    Haba, Reiji
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2010, 91 (02) : 333 - 335
12345